A Line D-T Neutron Source Facility for Annular Blanket Experiment: Phase III of the JAERI/USDOE Collaborative Program on Fusion Neutronics

1991 ◽  
Vol 19 (3P2B) ◽  
pp. 1873-1878 ◽  
Author(s):  
T. Nakamura ◽  
Y. Oyama ◽  
Y. Ikeda ◽  
C. Konno ◽  
H. Maekawa ◽  
...  
Keyword(s):  
Neutron Source ◽  
Phase Iii ◽  
Collaborative Program

Annular Blanket Experiment Using a Line DT Neutron Source: Phase IIIA of the JAERI/USDOE Collaborative Program on Fusion Neutronics

1991 ◽  
Vol 19 (3P2B) ◽  
pp. 1879-1884 ◽  
Author(s):  
Y. Oyama ◽  
C. Konno ◽  
Y. Ikeda ◽  
H. Maekawa ◽  
K. Kosako ◽  
...  
Keyword(s):  
Neutron Source ◽  
Collaborative Program ◽  
Source Phase

Phase III experimental results of JAERI/USDOE collaborative program on fusion neutronics

1991 ◽  
Vol 18 ◽  
pp. 203-208 ◽  
Author(s):  
Y. Oyama ◽  
C. Konno ◽  
Y. Ikeda ◽  
H. Maekawa ◽  
F. Maekawa ◽  
...  
Keyword(s):  
Experimental Results ◽  
Phase Iii ◽  
Collaborative Program

scholarly journals Status of DOE/JAERI collaborative program phase II and phase III capsules

1997 ◽  
Author(s):  
J P Robertson ◽  
K E Lenox ◽  
I Ioka ◽  
E Wakai
Keyword(s):  
Phase Ii ◽  
Phase Iii ◽  
Collaborative Program

RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium falciparum

2017 ◽  
Vol 1 (6) ◽  
pp. 533-537
Author(s):  
Lorenz von Seidlein ◽  
Borimas Hanboonkunupakarn ◽  
Podjanee Jittmala ◽  
Sasithon Pukrittayakamee
Keyword(s):  
Protective Efficacy ◽  
Age Groups ◽  
Sub Saharan Africa ◽  
Phase Iii ◽  
European Medicines Agency ◽  
Older Children ◽  
Pivotal Phase ◽  
Malaria Epidemiology ◽  
Maximum Benefit ◽  
Sub Saharan

RTS,S/AS01 is the most advanced vaccine to prevent malaria. It is safe and moderately effective. A large pivotal phase III trial in over 15 000 young children in sub-Saharan Africa completed in 2014 showed that the vaccine could protect around one-third of children (aged 5–17 months) and one-fourth of infants (aged 6–12 weeks) from uncomplicated falciparum malaria. The European Medicines Agency approved licensing and programmatic roll-out of the RTSS vaccine in malaria endemic countries in sub-Saharan Africa. WHO is planning further studies in a large Malaria Vaccine Implementation Programme, in more than 400 000 young African children. With the changing malaria epidemiology in Africa resulting in older children at risk, alternative modes of employment are under evaluation, for example the use of RTS,S/AS01 in older children as part of seasonal malaria prophylaxis. Another strategy is combining mass drug administrations with mass vaccine campaigns for all age groups in regional malaria elimination campaigns. A phase II trial is ongoing to evaluate the safety and immunogenicity of the RTSS in combination with antimalarial drugs in Thailand. Such novel approaches aim to extract the maximum benefit from the well-documented, short-lasting protective efficacy of RTS,S/AS01.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Phase III Study Makes Case for IV Chemoradiation

2007 ◽  
Vol 38 (1) ◽  
pp. 46-47
Author(s):  
BRUCE WILSON
Keyword(s):  
Phase Iii ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document